Vaccines targeting the hypoglycosylated MUC1 are one modality being developed by us and others in an effort to induce antibodies and T cells that can eliminate inflammation and/or tumor initiating cells that express this form of MUC1, thereby preventing further inflammation and promoting anti-tumor activity of many effector cells in the microenvironment. The gene discussed is MUC1; the disease is neoplasm.